Teva launches generic version of Valeant's Uceris in U.S.

|By:, SA News Editor

Teva Pharmaceutical Industries (TEVA +0.4%) announces the U.S. commercial launch of its generic version of Valeant Pharmaceuticals' (VRX +3.1%) UC med Uceris (budesonide) extended-release tablets, 9 mg.

Per IQVIA, the U.S. market is ~$196M.

Subscribe for full text news in your inbox